Skip to main content

Table 7 Baseline characteristics from post-hoc analysis

From: A randomized controlled pilot study to evaluate the effect of an enteral formulation designed to improve gastrointestinal tolerance in the critically ill patient—the SPIRIT trial

  Patients with diarrhea (n = 60) Patients without diarrhea (n = 30) p value
Receiving Peptamen® AF n = 60 29 (48%) n = 30 17 (57%) 0.51
Age, years n = 60 63.7 (51.0–74.3) n = 30 61.7 (50.5–72.8) 0.71
Sex, male n = 60 41 (68%) n = 30 20 (67%) 1.00
Body mass index, kg/m2 n = 54 28.1 (23.6–33.8) n = 28 28.2 (23.9–32.6) 0.83
APACHE II score n = 57 30.0 (25.0–36.0) n = 29 26.0 (20.0–30.0) 0.005
SAPS II score n = 60 66.0 (53.5–76.8) n = 30 52.0 (43.8–63.8) 0.003
Diabetes n = 60 12 (20%) n = 30 9 (30%) 0.30
Residual gastric volume at study inclusion, ml n = 58 41.0 (20.0–112.5) n = 27 30.0 (10.0–80.0) 0.19
Presence of diarrhea at study inclusion n = 60 8 (13%) n = 30 1 (3%) 0.26
Blood glucose at study inclusion, mmol/l n = 60 8.2 (7.0–9.4) n = 30 8.0 (6.6–8.9) 0.43
  1. Continuous variables are presented as median (interquartile range) and categorical variables as number of patients (%)
  2. APACHE Acute Physiology and Health Evaluation, SAPS Simplified Acute Physiology Score